PLoS ONE · 2021 · 48 citations · 49 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationMolecular VirologyVaccinologyDna VaccinesNucleic Acid VaccinesRecombinant Protein VaccinesVaccinationVaccine Antigen DiscoveryViral VaccinesDeoxyribonucleic Acid (Dna) VaccineDna Vector VaccinesNeutralizing Antibody ProductionNeutralizing Antibody ResponsesSars-cov-2 InfectionT-cell Immune ResponsesT-cell Mediated ResponsesTh1 Immune Response
More than 65 million people have been confirmed infection with SARS-CoV-2 and more than 1 million have died from COVID-19 and this pandemic remains critical worldwide. Effective vaccines are one of the most important strategies to limit the pandemic. Here, we report a construction strategy of DNA vaccine candidates expressing full length wild type SARS-CoV-2 spike (S) protein, S1 or S2 region and their immunogenicity in mice. All DNA vaccine constructs of pCMVkan-S, -S1 and -S2 induced high levels of specific binding IgG that showed a balance of IgG1/IgG2a response. However, only the sera from mice vaccinated with pCMKkan-S or -S1 DNA vaccines could inhibit viral RBD and ACE2 interaction. The highest neutralizing antibody (NAb) titer was found in pCMVkan-S group, followed by -S1, while -S2 showed the lowest PRNT50 titers. The geometric mean titers (GMTs) were 2,551, 1,005 and 291 for pCMVkan-S, -S1 and -S2, respectively. pCMVkan-S construct vaccine also induced the highest magnitude and breadth of T cells response. Analysis of IFN-γ positive cells after stimulation with SARS-CoV-2 spike peptide pools were 2,991, 1,376 and 1,885 SFC/106 splenocytes for pCMVkan-S, -S1 and -S2, respectively. Our findings highlighted that full-length S antigen is more potent than the truncated spike (S1 or S2) in inducing of neutralizing antibody and robust T cell responses.
49
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell · 2020 · 9.1K citations · Full text
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael et al. · New England Journal of Medicine · 2020 · 3.5K citations · Full text
Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text